News

Article

IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer

Author(s):

Fact checked by:

Key Takeaways

  • IMM-1-104 combined with gemcitabine/nab-paclitaxel achieved a 43% ORR and 86% DCR in first-line pancreatic cancer patients.
  • IMM-1-104 with modified FOLFIRINOX showed tumor shrinkage in all evaluable patients, including a 100% reduction in one case.
SHOW MORE

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

lertsakwiman – stock.adobe.com

lertsakwiman – stock.adobe.com

The addition of IMM-1-104, a deep cyclic MEK inhibitor, to modified gemcitabine and nab-paclitaxel (Abraxane) led to responses and disease control as first-line therapy for patients with pancreatic cancer, according to data from phase 2a trial (NCT05585320).

Updated results from the phase 2a portion of the trial showed that IMM-1-104 plus modified gemcitabine and nab-paclitaxel generated an overall response rate (ORR) of 43% and a disease control rate (DCR) of 86% in evaluable patients (n = 7). Among responders, 1 patient had a complete response, and 3 patients achieved a partial response (PR). Three patients had stable disease.

"We are excited to report an updated ORR of 43% and DCR of 86% for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in [patients with] first-line pancreatic cancer. For reference, the benchmark reported for gemcitabine/nab-paclitaxel in this setting [was] an ORR of 23% and DCR of 48%,” Ben Zeskind, PhD, chief executive officer of Immuneering, stated in a news release.

Initial data from another cohort of the phase 2a study evaluating IMM-1-104 in combination with modified FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) demonstrated that all evaluable patients (n = 4) experienced tumor shrinkage. One patient had 100% tumor shrinkage and a confirmed PR . One other patient had an unconfirmed PR, and 2 patients had stable disease.

“Today we are also sharing initial data from IMM-1-104 in combination with modified FOLFIRINOX in [patients with] first-line pancreatic cancer,” Zeskind added. “We observed target lesion shrinkage across all evaluable patients, including a 100% reduction, a rare event in this patient population.”

In another phase 2a cohort, IMM-1-104 monotherapy generated an ORR of 5% in patients with second-line pancreatic cancer (n = 21). The DCR was 52%.

The open-label, nonrandomized phase 1/2 trial enrolled patients at least 18 years of age with histologically or cytologically locally advanced unresectable or metastatic solid tumors harboring a RAS activating mutation to receive IMM-1-104 monotherapy during the phase 1 portion; in phase 2a, patients needed to have locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), RAS-mutant melanoma, or RAS-mutant non–small cell lung cancer (NSCLC) to receive the agent alone.2 Patients with locally advanced or metastatic PDAC were allowed to enroll to receive IMM-1-104–based combinations in both phases of the study. All patients needed to have measurable disease per RECIST 1.1 criteria, an ECOG performance status of 0 or 1, and adequate organ function.

The study included 3 treatment groups: IMM-1-104 monotherapy given once per day for those with first- or second-line PDAC, first-, second-, or third-line melanoma, or second- or third-line NSCLC; IMM-1-104 plus modified gemcitabine and nab-paclitaxel for first-line PDAC; and IMM-1-104 plus modified FOLFIRINOX for first-line PDAC.

The primary end point of phase 2 was ORR. Secondary end points included DCR, progression-free survival, duration of response, 3- and 6-month overall survival (OS), and OS.

Safety data for patients with PDAC treated with IMM-1-104 alone in the second-line setting (n = 21) showed that the most common treatment-related adverse effects (TRAEs) that occurred in at least 10% of patients included rash (29%), diarrhea (24%), fatigue (19%), nausea/vomiting (14%), and blurred vision (14%).1

“No grade 3 or grade 4 [TRAEs] were observed [with IMM-1-104 monotherapy], and only a handful of grade 2 [TRAEs] were observed,” Brett Hall, PhD, chief scientific officer of Immuneering, stated in a news release.

Immuneering is planning to expand the phase 2a trial to include 3 additional combination arms. These additional arms will evaluate IMM-1-104 plus a BRAF inhibitor for patients with melanoma; and IMM-1-104 plus checkpoint inhibitors for patients with melanoma or NSCLC. Additional phase 2a data are expected to readout in the second quarter of 2025.

“The maturing safety profile for IMM-1-104 gives us confidence that Immuneering may have developed a better tolerated MEK-inhibitor with exciting potential for vertical, immune-modifying, and orthogonal combinations. We expect to share expanded development plans for IMM-1-104 beyond pancreatic cancer, as we continue to explore options with investigators and third parties,” Hall added.

Related Videos
Ignacio Garrido-Laguna, MD, PhD, MBA
 Dr Dotan on the Prognostic Value of QOL Assessments in Older Patients with Pancreatic Cancer
Dr Oberstein on Data for Pamrevlumab Plus Nab-Paclitaxel/Gemcitabine in PDAC
Alexander I. Spira, MD, PhD, FACP
Ajay Goel, PhD, AGAF, of City of Hope National Medical Center
Suneel Kamath, MD
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.